Teva Pharmaceuticals USA

Bard Access Systems is one of the leading companies that offers a range of vascular access devices in the United States. It manufactures and sells medical devices that are used in circulatory and other select systems. The company provides central venous catheters in a variety of models. Bard Access Systems offers a range of ports and feeding devices. It also provides a variety of ultrasound and drainage products. The company offers a range of accessories, such as tunnelers, suture wings, catheter clamps, injection caps and replacement connectors. Bard Access Systems has a staff of more than 300 employees. It administers the Assessment Advantage program and provides a variety of midline and dialysis catheters.

Avantor Performance Materials, nestled in North Salt Lake, UT, stands as a beacon of innovation in the realm of manufacturing. This facility epitomizes precision and excellence, with a dedication to crafting high-quality materials that cater to a myriad of industries. From cutting-edge research to meticulous production processes, Avantor Performance Materials prides itself on delivering products that exceed expectations. With a strategic location in North Salt Lake, UT, this manufacturer is strategically positioned to meet the demands of a dynamic market. The facility's state-of-the-art equipment and skilled workforce ensure that each product meets stringent quality standards. Avantor Performance Materials seamlessly combines technology and expertise to drive advancements in manufacturing, making it a pivotal player in the industry. Generated using this place's available information

Curza is a small-molecule therapeutics company based in Salt Lake City, UT, dedicated to developing novel classes of antibiotics to combat the global threat of antibiotic resistance. With a focus on infectious diseases, Curza has developed several structurally distinct classes of proprietary drugs, including CZ-02, a new class of broad spectrum antibiotics targeting drug-resistant Gram-negative bacteria. Driven by the rising epidemic of antibiotic resistance, Curza's goal is to address the urgent need for effective antibiotics, as antibiotic resistance contributes to the death of 5,000,000 people annually. Through their innovative ribosomal antibiotics program, Curza aims to develop antibiotics that show both selectivity and potent activity against ESKAPE pathogens, while also focusing on developing antibiofilm antibiotics to combat biofilm-related infections.Generated from the website